心脈醫療(688016.SH)2019年度淨利潤升56.38%至1.42億元 擬10派6.5元
格隆匯3月29日丨心脈醫療(688016.SH)披露2019年年度報告,實現營業總收入3.34億元,同比增長44.39%;營業利潤1.64億元,同比增長56.67%,歸屬於母公司的淨利潤1.42億元,同比增長56.38%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.21億元,同比增長44.92%;基本每股收益2.31元,擬每10股派發現金紅利6.5元(含税)。
公司主要從事主動脈及外周血管介入醫療器械的研發、生產和銷售。在主動脈介入醫療器械領域,公司是國內產品種類齊全、規模領先、具有市場競爭力的企業,公司在該領域的主要產品為主動脈覆膜支架系統;在外周血管介入醫療器械領域,公司深耕多年,目前擁有外周血管支架系統、外周血管球囊擴張導管等產品;另外,公司擁有國內唯一獲批上市的可在胸主動脈夾層外科手術中使用的術中支架系統。
公司始終以“持續創新,為主動脈及外周血管疾病患者提供能挽救患者生命或改善其生活質量的最佳普惠醫療解決方案”為使命,致力於成為主動脈與外周血管介入治療領域全球領先的高科技公司。
經過多年潛心研發,公司掌握了涉及治療主動脈疾病的覆膜支架系統的核心設計及製造技術,成功開發出第一個國產腹主動脈覆膜支架、國內唯一獲批上市的可在胸主動脈夾層外科手術中使用的術中支架系統。公司自主研發的Castor分支型主動脈覆膜支架首次將TEVAR手術適應證拓展到主動脈弓部病變,是全球首款獲批上市的分支型主動脈支架。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.